Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.

Thomas Höfner, Sonia Vallet, Boris A Hadaschik, Sascha Pahernik (Co-author), Stefan Duensing, Markus Hohenfellner, Dirk Jäger, Carsten Grüllich

    Research output: Contribution to journalOriginal Article (Journal)peer-review

    5 Citations (Web of Science)
    Original languageEnglish
    Pages (from-to)833-839
    JournalWORLD JOURNAL OF UROLOGY
    Volume33
    Issue number6
    DOIs
    Publication statusPublished - 2015

    Keywords

    • ANTITUMOR-ACTIVITY
    • INCREASED SURVIVAL
    • CROSS-RESISTANCE
    • ENZALUTAMIDE
    • CHEMOTHERAPY
    • MITOXANTRONE
    • PREDNISONE
    • MEN

    Cite this